贝伐单抗抑制角膜新生血管的实验研究

目的评价贝伐单抗（avastin）局部应用对小鼠角膜新生血管（CNV）的抑制作用。方法通过碱烧伤建立CNV模型,将30只Balb／c小鼠随机分成5组,A组贝伐单抗1mg／mL每日点眼2次;B组贝伐单抗3mg／mL每日点眼2次;C组贝伐单抗5mg／mL每日点眼2次;D组0．1％地塞米松每日点眼2次;E组生理盐水每日点眼2次。分别于术后3、7、14d观察CNV情况并拍照。术后第14天,处死全部小鼠,行CNV内皮细胞荧光标记,计算CNV所占全角膜面积的比例。结果各组CNV面积为A组（37．11±3．17）％、B组（29．75±3．56）％、C组（18．76±2．55）％、D组（20．91±2．75）％,E组（41．65±2．11）％。各组小鼠CNV面积依次为c组〈D组〈B组〈A组〈E组,C组同A、B、E组比较差异均有统计学意义（P〈0．01）,c组与D组比较差异无统计学意义（P=0．694）。结论局部应用贝伐单抗对小鼠角膜化学烧伤后的CNV有抑制作用。     

Inhibition of corneal neovascularization after alkali burn: comparison of different doses of bevacizumab in monotherapy or associated with dexamethasone

Background: To compare the effects of different doses of bevacizumab with both saline and dexamethasone on inflammatory angiogenesis in the rat cornea induced by small chemical lesions. Methods: Corneal chemical cauterization was performed on 24 rats. Animals were divided randomly into six groups and received a daily subconjunctival injection for 7 days of: balanced salt solution 0.1 mL or dexamethasone phosphate 4 mg/day or bevacizumab 2.5 mg/day, 3.75 mg/day, 5.0 mg/day or bevacizumab 5.0 mg/day + dexamethasone phosphate 4 mg/day. Clinical examination under slit lamp was performed daily for 7 days to evaluate corneal opacity and vessel size evolution. Computer‐assisted quantitative image analysis was used to measure the total corneal area covered by neovascularization. Results: At final examination, the dexamethasone, bevacizumab 5.0 mg/day and dexamethasone + bevacizumab groups showed a significant lowering in corneal opacity score as compared with control (P = 0.024, P = 0.006 and P = 0.013, respectively). Also, a significant reduction on new vessels size score was observed. Surface of corneal neovascularization was significantly reduced in dexamethasone, bevacizumab 5.0 mg/day and dexamethasone + bevacizumab groups compared with control (P = 0.045, P = 0.047 and P = 0.044, respectively). Conclusion: Our study demonstrates the ability of a 5.0 mg/day bevacizumab subconjunctival injection, in monotherapy or associated with dexamethasone, to cause a short‐term involution of corneal neovascularization after corneal alkali burn. Combination of both of these treatments may have advantages to monotherapy approaches.     

Comparison of the effects of bevacizumab and ranibizumab injection on corneal angiogenesis in an alkali burn induced model

AIM: To investigate the effects of bevacizumab and ranibizumab on corneal neovascularization in an alkali burn-induced model of corneal angiogenesis. METHODS: Fifteen Wistar albino rats were divided randomly into 3 groups after chemical cauterization of the cornea. The first group received a single dose of 0.1mL saline solution as a control group whereas second and third groups received a single dose of 2.5mg bevacizumab or 1mg ranibizumab by subconjunctival injection, respectively. After three weeks, the rat corneas were evaluated by biomicroscopy and corneal photographs were taken. The percentage of neovascularization area, length of the longest new vessel, corneal edema and corneal opacity scores were assessed. RESULTS: The analysis of digital photographs showed that the percentage of neovascularization area to the total corneal area, the length of the longest new vessel, corneal edema and opacity scores were significantly lower in both study groups compared to the control group (P<0.05). Additionally, the percentage of corneal neovascularization area, the length of the longest new vessel and corneal opacity score were less with bevacizumab than ranibizumab. CONCLUSION: Subconjunctival bevacizumab and ranibizumab treatments may be effective methods in reducing corneal neovascularization. Furthermore, bevacizumab is more effective than ranibizumab in the inhibition of corneal neovascularization.     

Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model

PURPOSE: To evaluate the effect of subconjunctival injection of bevacizumab on experimentally induced corneal neovascularization. DESIGN: Experimental animal study. METHODS: Twelve New Zealand white rabbits were involved, divided equally into four groups. Only one eye per rabbit was used. Topical instillation of 10 microl 5% NaOH solution was used, under general anesthesia, to induce corneal neovascularization secondary to corneal alkali burn in groups 2, 3, and 4. A single dose of 3.75 mg (25 mg/ml) bevacizumab was injected subconjunctivally. Group 1 (control group 1) was neither cauterized nor treated. Group 2 (control group 2) received a sham injection of balanced salt solution on day 14. Group 3 was treated on day 14 (after corneal neovascularization had been established). Group 4 was treated on day 1. Digital photographs were obtained and analyzed during the entire 28-day procedure. The area of neovascularization and scarring were measured in terms of the percentage of corneal surface affected. RESULTS: On day 28, the difference of neovascularization between groups 2, 3, and 4 was found to be statistically significant at the .05 level (one-way analysis of variance [ANOVA]): group 4 (4.7%+/-3.1%).1, one-way ANOVA). No side effects were noted. CONCLUSIONS: Subconjunctival administration of bevacizumab inhibits corneal neovascularization effectively in the rabbit experimental model, especially if administered early.     

Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis

BACKGROUND: New and uncontrolled blood vessel development in the cornea is a pivotal process in the pathogenesis of several corneal diseases. These corneal diseases may finally cause blindness and managing them therapeutically is problematic. The data supporting a causal role for vascular endothelial growth factor in corneal neovascularization are extensive. This study aimed to evaluate the effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in rabbits. METHODS: Chemical cauterization of the cornea was performed by touching central cornea with a 5-mm-diameter NaOH-soaked cotton applicator for 10 s in 20 eyes of 20 White New Zealand rabbits. The rabbits were then divided randomly into two equal groups. Bevacizumab (2.5 mg) was administered to 10 eyes (group 1) by a subconjunctival injection immediately after chemical cauterization of corneal surface. As a control, 10 eyes (group 2) received an injection of distilled water. Rabbits were examined daily for detection of the first signs of neovascularization. Three weeks later, the extent of corneal neovascularization was evaluated by direct examination and photograph analyses. Total corneal neovascularization area, degree of circumference involved and longest neovascular pedicle length were assessed. RESULTS: Bevacizumab significantly decreased the total neovascularization area (P < 0.009), the circumference involved (P < 0.011) and the longest neovascular pedicle length (P < 0.023). CONCLUSION: Local injection of bevacizumab has a significant effect on inhibition of alkali burn-induced corneal neovascularization. This shows the potential value of bevacizumab in the treatment of corneal neovascularization.     

Topical bevacizumab and ocular surface neovascularization in patients with stevens-johnson syndrome

PURPOSE: To evaluate the efficacy and safety of topical bevacizumab on ocular surface neovascularization among patients with Stevens-Johnson syndrome. METHODS: This was a retrospective, interventional case report. Three eyes of 2 patients were examined. Bevacizumab (25 mg/mL) eyedrops were applied 4 times daily for a period of 3 months. Main outcome measures were improvement of symptoms, visual acuity, degree of ocular surface neovascularization, corneal opacification, conjunctival injection, and occurrence of adverse events. RESULTS: Both patients completed the 3-month observation period and reported that it significantly improved ocular comfort. At the end of the study period, visual acuity improved in all 3 eyes; all eyes were observed to have decreased ocular surface neovascularization, corneal opacification, and conjunctival injection. No serious adverse events were reported. CONCLUSIONS: Topical bevacizumab is well tolerated and may be effective in improving comfort and inducing regression of ocular surface neovascularization, conjunctival injection, and corneal opacification in patients with ocular surface disease caused by Stevens-Johnson syndrome. Further controlled and long-term studies are needed to fully evaluate the long-term effects of this novel treatment.     

血管抑素抑制大鼠角膜新生血管的研究

目的研究血管抑素（AS）对大鼠角膜碱烧伤后新生血管的抑制作用。方法120只Wistar大鼠制作碱烧伤角膜新生血管（CNV）模型,随机分为4组,分别为2.5μgAS组、5μgAS组、地塞米松组、生理盐水组,每组30只。分别给予2.5μg/0.1mLAS、5μg/0.1mLAS、0.1mg/0.1mL地塞米松、生理盐水各0.1mL,球结膜下注射,隔日1次,共4次。在大鼠角膜碱烧伤后不同时间裂隙灯下观察大鼠角膜混浊度,计算新生血管面积,分析角膜组织病理切片。结果2.5μgAS组、5μgAS组及地塞米松组在第7、10、14天较生理盐水组角膜混浊程度轻,差异均有统计学意义（P〈0.05）;2.5μgAS组、5μgAS组及地塞米松组在碱烧伤后第3天起各时间点新生血管面积小于生理盐水组,差异均有统计学意义（P〈0.05）。结论AS能有效抑制大鼠角膜碱烧伤后CNV的形成。     

The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization

Acta Ophthalmol. 2010: 88: 862–867

Abstract.

Purpose: This study aimed to evaluate the effects of different concentrations of topically administered bevacizumab (Avastin) on experimental corneal neovascularization (NV) in rats. Methods: Corneal NV was induced by chemical cauterization with silver nitrate sticks applied to the centre of the corneas of 37 Wistar rats. The rats were then randomized to four topical treatment groups: group 1 (n = 10) received 4 mg/ml bevacizumab; group 2 (n = 9) received 2 mg/ml bevacizumab; group 3 (n = 10) received 1 mg/ml bevacizumab, and group 4 (n = 8) represented a control group and received saline. All drops were initiated immediately after cauterization and applied twice per day for 7 days. Corneal NV was assessed 8 days after cauterization in a masked fashion, both qualitatively by clinical evaluation and quantitatively by blood vessel count in photographs of histological sections. Results: On clinical evaluation, groups 1 and 2 showed significantly less NV compared with the saline‐treated control group (p = 0.006 and p = 0.024, respectively). Histopathological evaluation showed that only group 1 differed significantly from controls (5% significance level) and normal corneal epithelium was seen in all groups. Conclusions: Topically administered bevacizumab at a concentration of 4 mg/ml significantly reduces corneal NV according to both clinical and histopathological evaluations; lower concentrations were less effective on both parameters. No corneal epitheliopathy was found using these concentrations.     

Comparison of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal neovascularization in a rat model

AIM:To compare the efficacies of subconjunctival bevacizumab, ranibizumab, and pegaptanib sodium injections for the inhibition of corneal neovascularization in an experimental rat model. METHODS:Sixteen corneas of 16 rats were chemically cauterized and randomized into four groups:bevacizumab group that treated with 0.05mL/1.25mg bevacizumab, ranibizumab group that treated with 0.05mL/0.5mg ranibizumab, pegaptanib group that treated with 0.05mL/0.15mg pegaptanib sodium, and control group that treated with 0.05mL saline solution. Digital photographs of the corneas were taken and analyzed using an image analysis software program. All corneas were excised and examined histologically on the 15^th day. RESULTS: Each treatment group had significantly less neovascularized corneal areas and fewer blood vessels than the control group (all P<0.05). In addition, bevacizumab group had significantly less neovascularized corneal areas and fewer blood vessels than ranibizumab and pegaptanib groups (both P<0.05). However, there was no significant difference between the ranibizumab and pegaptanib groups regarding percentage of neovascularized corneal areas and number of blood vessels (both P>0.05). CONCLUSION:Subconjunctival bevacizumab, ranibizumab, and pegaptanib sodium were effective with no corneal epitheliopathy for inhibiting corneal neovascularization after corneal burn in rats. Bevacizumab was more effective than ranibizumab and pegaptanib sodium.     

Avastin两种用药方法抑制大鼠角膜碱烧伤后早期新生血管增生的比较

目的:探讨avastin滴眼液和结膜下注射方法对SD大鼠角膜碱烧伤后早期新生血管增生的影响。方法:制作SD大鼠角膜碱烧伤动物模型,随机分成3组,A组(对照组)、B组(avastin滴眼液组)、C组(avastin结膜下注射组),每组20只。各组分别在烧伤后3,5,7,14d应用裂隙灯显微镜观察角膜新生血管(cornealneovascu-larization,CNV)增生情况,拍照并计算CNV面积变化。同时每组各处死大鼠5只,摘取角膜组织,采用免疫组织化学方法检测VEGFR-2的表达,免疫荧光法检测CD31表达。结果:A组在伤后各时段CNV增生面积均大于B,C组;B,C组伤后各个时段VEGFR-2及CD31的表达均显著低于A组,差异有统计学意义(P<0.01);而B,C两组之间CNV增生面积及伤后各时段VEGFR-2及CD31的表达差异无统计学意义(P>0.01)。结论:角膜碱烧伤后早期应用avastin滴眼液和结膜下注射均能有效地抑制CNV生成。     

Avastin对大鼠角膜新生血管的抑制及超微结构的影响

目的:探讨Avastin对角膜新生血管形成及角膜内血管内皮生长因子(VEGF)的影响及其超微结构的影响。方法:Wistar大鼠96只随机分3组,采用碱烧伤的方法制备大鼠角膜新生血管模型;正常不烧伤组4只。烧伤后隔日球结膜下注射0.1mL生理盐水组32只,烧伤后隔日球结膜下注射Avastin0.1mL组32只,烧伤后隔日球结膜下注射地塞米松0.1mL组32只。碱烧伤术后在裂隙灯显微镜下观察大鼠角膜混浊度;宏观测量新生血管长度;组织病理切片HE染色作微血管计数;透射电镜观察超微结构的改变;免疫组化检测角膜VEGF的蛋白表达情况;CD34标记新生血管,显微镜下微血管计数方法研究角膜新生血管形成及抑制情况。结果:治疗组在3,7,10,14d较对照组角膜混浊程度轻(P<0.05);14d形成的新生血管数量较对照组少(P<0.05)。实验组新生血管微血管数量减少,VEGF蛋白表达下降,具有统计学差异。VEGF主要表达在角膜受损区的感染细胞胞质内,其出现时间与位置与角膜新生血管一致。Avastin和地塞米松均可有效抑制角膜新生血管,减少角膜内VEGF表达,两者无统计学差异,结膜下注射Avastin和地塞米松后,大鼠角膜超微结构无除烧伤后其它显著改变。结论:Avastin和地塞米松可抑制角膜新生血管,减少角膜内VEGF表达,对角膜的超微结构均无显著毒性。     

Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model

Aims: To evaluate and compare the inhibitory effects of topical and subconjunctival bevacizumab on corneal neovascularization in a rat model. Methods: Twenty corneas of 20 rats were chemically cauterized with silver nitrate sticks. Animals were randomized into four groups: a control group that received only topical artificial tear drops twice daily, a subconjunctival injection group that received 1.25 mg (0.05 ml) of bevacizumab on the 1st, 4th, and 7th day, and two topical bevacizumab groups that received instillation of 4 or 12.5 mg/ml bevacizumab twice daily. Digital photographs of the cornea were taken and analyzed using an image analysis software program. On the 10th day, corneas were excised and examined histologically. Results: The mean percentage of the vascularized corneal area (%) in the control group was 63.32 ± 13.10 (mean ± SD), compared with 30.22 ± 15.73 in the subconjunctival injection group, 26.76 ± 10.23 in the 4-mg/ml topical group, and 25.52 ± 12.45 in the 12.5-mg/ml group. The differences between the control and each treatment group were significant (all p < 0.01). Further, histological examination revealed that each treatment group had fewer vessels than the control group (all p < 0.01). Conclusions: Both subconjunctival injection and topical use of bevacizumab are effective and safe in controlling corneal neovascularization.     

Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin®) eye drops against corneal neovascularization

Purpose

To evaluate the short- and long-term in vivo safety and efficacy of topical bevacizumab (Avastin) application for treatment of corneal neovascularization secondary to a variety of corneal diseases.

Methods

Thirty eyes of 27 patients with progressive corneal neovascularisation (not responding to conventional anti-inflammatory treatment) due to different underlying corneal diseases received topical bevacizumab (Avastin) eye drops (5 mg/ml Bevacizumab) for 0.5–12 months (five times/day on average). At each visit, a routine Snellen visual acuity assessment was performed, followed by ophthalmic examination including fluorescein staining. Changes of corneal neovascularization and vessel diameter were assessed using morphometry of standardized digital corneal photographs.

Results

Five patients (five eyes) developed new corneal epithelial defects during topical bevacizumab treatment. In 22 patients, no new epithelial defects were observed. None of the 27 patients complained about any drug-related ocular or systemic adverse events during follow-up. No allergic reactions were observed. Corneal photographs of 21 eyes (19 patients) could be assessed. The mean reduction in vascularized area during treatment was 61%. The mean reduction in vessel diameter under topical Avastin therapy was 24%.

Conclusions

Off-label topical bevacizumab therapy against corneal neovascularization secondary to different corneal diseases was generally well-tolerated for up to 12 months. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization, and lead to a reduction of the vessel diameter. Our results suggest that off-label use of Bevacizumab eye drops is a relatively safe and well-tolerated option for the treatment of corneal neovascularization. Care should be taken in patients with epithelial defects and neurotrophic keratopathy.     

Subconjunctival bevacizumab for corneal neovascularization

Acta Ophthalmol. 2010: 88: 868–871

Abstract.

Purpose: This work aimed to study and evaluate the effect of subconjunctival bevacizumab injection in patients with corneal neovascularization (CNV) resulting from different ocular surface disorders. Methods: Ten eyes with CNV caused by different ocular surface disorders were studied. All eyes had both major and minor vessel CNV caused by factors such as healed corneal ulcers, long‐standing chronic inflammatory diseases and corneal ischaemia (caused by contact lenses). All eyes received a single subconjunctival injection of 2.5 mg (0.1 ml) bevacizumab. Morphological changes in the major and minor vessels were evaluated using slit‐lamp biomicroscopy and corneal photography. Results: Conspicuous recession of the minor vessels of CNV was observed in all eyes at 2 weeks post‐injection. The extent of CNV of the major vessels was significantly decreased at 2 weeks post‐injection. The level of CNV continued to decrease noticeably for 3 months and then stabilized for the remainder of the 6‐month follow‐up period. Parameters used for evaluation included the total area of CNV, which amounted to 14.0 ± 5.4% of the corneal surface pre‐injection, compared with 9.4 ± 3.9% post‐injection (p < 0.01), reflecting a mean decrease in CNV of 33 ± 8%, and the extent of neovascularization, which decreased from 4.3 ± 1.5 clock hours pre‐injection to 2.4 ± 1.1 clock hours post‐injection (p < 0.01). During the 6‐month follow‐up, none of the 10 eyes showed any complication that could be related to subconjunctival bevacizumab injection. Conclusions: Bevacizumab can be used safely and effectively for CNV resulting from different ocular surface disorders. It represents an effective treatment for minor vessel neovascularization caused by long‐standing chronic inflammation (e.g. trachoma) or long‐standing corneal ischaemia (e.g. contact lenses), as well as for major vessel neovascularization resulting from different causes. Bevacizumab was well tolerated over the 6‐month follow‐up period.     

PXN-pY31、PXN-pY118在小鼠角膜新生血管形成中的表达变化

目的　探讨Paxillin（PXN）-pY³¹、PXN-pY¹¹⁸在小鼠角膜碱烧伤后角膜新生血管形成过程中的表达变化。方法　取健康6~8周龄雄性C57BL6小鼠36只,均右眼建立角膜碱烧伤模型为实验组,左眼不作任何处理为对照组,观察碱烧伤后1 d、3 d、5 d、7 d、10 d、14 d 角膜新生血管情况,并行免疫组织化学染色;Western blot 检测实验组碱烧伤后1 d、3 d、5 d、7 d时PXN-pY³¹、PXN-pY¹¹⁸在角膜中的表达变化。结果　对照组角膜无新生血管生成,PXN-pY³¹、PXN-pY¹¹⁸在角膜中未见表达。实验组角膜新生血管长度、钟点数及面积随着碱烧伤后时间的延长均呈曲线样改变。免疫组织化学染色检测结果显示,实验组角膜中PXN-pY³¹、PXN-pY¹¹⁸的表达均较对照组增强,其动态过程与角膜新生血管的发展进程一致。Western blot检测结果示,实验组碱烧伤后3 d PXN-pY³¹,PXN-pY¹¹⁸的表达显著升高;碱烧伤后5 d,PXN-pY³¹、PXN-pY¹¹⁸的表达达到高峰;碱烧伤后7 d,PXN-pY³¹、PXN-pY¹¹⁸表达开始下降。碱烧伤后3 d、5 d、7 d时PXN-pY³¹、PXN-pY¹¹⁸的表达与碱烧伤后1 d相比,差异均有统计学意义（均为P<0.05）。结论　PXN-pY³¹、PXN-pY¹¹⁸在角膜损伤的病理机制中发挥作用,其表达变化与角膜新生血管的生长情况相关。     

水通道蛋白1在大鼠角膜碱烧伤新生血管形成中的表达

目的检测大鼠角膜碱烧伤后新生血管形成过程中水通道蛋白1（AQP1）的表达变化,探讨其在角膜新生血管（CNV）形成中的作用。方法碱烧伤诱导CNV模型,将25只sD大鼠按处死的时间点不同分成5组,每组5只。每日裂隙灯下观察CNV的生长情况,并采用免疫组织化学法和RT-PCR法检测AQP1及VEGF在大鼠CNV形成中的表达。结果在正常大鼠角膜组织中,AQP1和VEGF不表达或弱表达。碱烧伤后1d,AQP1表达开始增强,第7天表达最强,14d下降,21d时仍有弱表达。RT—PCR检测显示碱烧伤后AQP1表达增强,在伤后第7天表达最明显,21d后呈弱表达（t1d=3．491,t4d=10．690,t7d=12．936,t14d=10．767,t21d=8．594,P〈0．05）。免疫组织化学检测结果表明,VEGF与AQP1的表达分布相似,强度较弱,统计学分析表明二者的表达水平呈正相关（r=0．834,P〈0．05）。结论AQP1在碱烧伤后角膜巾的表达水平与新生血管的形成明显相关。     

人羊膜匀浆提取液抑制大鼠角膜碱烧伤后新生血管生成

目的:研究人羊膜匀浆提取液对角膜碱烧伤后新生血管形成过程中色素上皮衍生因子(pigment epithelium-derived fac-tor,PEDF)和血管内皮生长因子(vascular-endothelial growthfactor,VEGF)的表达影响及对角膜新生血管的抑制作用。方法:SD大鼠54只建立双眼角膜碱烧伤模型,随机分为3组:A组为3g/L氧氟沙星滴眼液组,B组为10g/L泼尼松龙滴眼液组,C组为新鲜人羊膜匀浆提取液组,并分别于治疗后不同时间点进行角膜新生血管增生情况观察,HE染色病理学观察,免疫组化行VEGF和PEDF的表达检测。结果:B,C组比A组新生血管增生少,多形核白细胞(poly-morphonuclear leukocyte,PMN)浸润程度轻,VEDF表达水平显著降低,但B,C两组之间VEDF表达无显著性差异(P>0.05)。C组PEDF表达水平显著高于A,B组(P<0.01),但A,B之间PEDF表达无显著性差异(P>0.05)。结论:新鲜人羊膜匀浆提取液能减少碱烧伤后角膜组织中PMN浸润,增强角膜组织PEDF的表达水平。     

Measurement of central corneal thickness and pre-corneal tear film thickness of rabbits using the Scheimpflug system

AIM:To measure central corneal thickness (CCT) and pre-corneal tear film thickness using the Galilei dual-Scheimpflug analyzer (GSA) in New Zealand white rabbits.METHODS:Ten normal New Zealand white rabbits (20 eyes) were included in this study. With the assistance of 0.1% fluorescein, the pre-corneal tear film can be well visualized. Both eyes of each rabbit were scanned once with the GSA pre- and post-instillation of 1μL 0.1% fluorescein. The difference between the two measurements of CCT (4-mm diameter) was recorded as the pachymetric values of the central tear film.RESULTS:The CCT of pre- and post-instillation was 388.8±9.5μm and 407.0±10.5μm, respectively. After a paired t-test analysis, the central pre-corneal tear film thickness of 4mm diameter was 18.2±5.31μm with a 95% confidence interval of (15.7, 20.6)μm (P<0.001).CONCLUSION:GSA can be used to measure CCT and analyze central tear film thickness of rabbits with the help of fluorescein.     

板层角膜移植时间对角膜碱烧伤后血清特异性抗体的影响

目的 通过动物角膜碱烧伤模型,观察烧伤后不同时期和烧伤后不同时间行板层角膜移植手术的新西兰白兔血清特异性抗体水平与组织病理的变化。方法 新西兰白兔20只,制作单侧眼角膜中央部中度碱烧伤模型并完全随机分为5组：烧伤组、早期移植组两组(即3d移植组、7d移植组)、中晚期移植组两组(即2周移植组、5周移植组)。制备正常及碱烧伤角膜蛋白提取液,用酶联免疫吸附试验(ELISA)检测每组兔不同时期血清抗角膜变性蛋白抗体水平,并取不同时期的角膜做光镜、电镜观察。结果 角膜碱烧伤后机体产生特异性抗体,2周时升高明显,5～6周达高峰,之后下降,8周时再次烧伤对侧眼角膜,抗体生成明显。早期移植组抗体升高不显著,而中晚期移植组抗体变化趋势与烧伤组基本相似。光、电镜结果显示：移植组与烧伤组比较,上皮愈合好,基质纤维排列整齐,炎细胞浸润轻,新生血管少;早期移植组比晚期移植组恢复更好。结论 早期板层角膜移植治疗角膜碱烧伤可阻断机体针对碱烧伤后角膜变性蛋白的体液免疫反应过程。     

兔角膜碱烧伤的共焦显微镜及病理观察

目的采用角膜共焦显微镜活体动态观察兔角膜碱烧伤的病理改变,组织化学方法观察角膜组织病理学变化。方法NaOH造成兔角膜碱烧伤模型,烧伤后4d、20d、36d行角膜共焦显微镜检查及组织病理学检查。结果碱烧伤后4d,角膜即有炎性细胞浸润,出现少许CD4+、CD8+细胞;碱烧伤后20d,角膜基质中炎性细胞浸润明显,CD4+、CD8+细胞增多,瘢痕及新生血管形成;碱烧伤后36d,炎性细胞浸润减少,CD4+、CD8+细胞消失,仍可见瘢痕及新生血管。结论角膜共焦显微镜活体观察碱烧伤后角膜的创伤修复,反映角膜的病理状态,有助于指导临床治疗。